 Daniel Sherbenou
Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 15 | 2024 | 100 | 6.370 |
Why?
| | Antibodies, Monoclonal | 8 | 2023 | 1284 | 1.940 |
Why?
| | Immunoconjugates | 3 | 2020 | 89 | 1.690 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2010 | 93 | 1.290 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 1390 | 1.190 |
Why?
| | Fusion Proteins, bcr-abl | 4 | 2010 | 61 | 1.050 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2020 | 671 | 0.950 |
Why?
| | Piperazines | 5 | 2010 | 316 | 0.940 |
Why?
| | Pyrimidines | 5 | 2010 | 382 | 0.900 |
Why?
| | Protein Kinase Inhibitors | 6 | 2019 | 811 | 0.820 |
Why?
| | Hydrazines | 1 | 2021 | 31 | 0.790 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2024 | 175 | 0.780 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2020 | 47 | 0.760 |
Why?
| | Membrane Cofactor Protein | 2 | 2018 | 12 | 0.760 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2021 | 540 | 0.760 |
Why?
| | Triazoles | 1 | 2021 | 134 | 0.720 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2023 | 900 | 0.700 |
Why?
| | Protein Biosynthesis | 1 | 2020 | 397 | 0.650 |
Why?
| | Antibodies, Neoplasm | 2 | 2018 | 30 | 0.630 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2017 | 156 | 0.520 |
Why?
| | ADP-ribosyl Cyclase 1 | 3 | 2024 | 36 | 0.490 |
Why?
| | Immunotherapy | 2 | 2017 | 493 | 0.490 |
Why?
| | Mutation | 4 | 2010 | 3457 | 0.470 |
Why?
| | Dexamethasone | 3 | 2021 | 320 | 0.470 |
Why?
| | Antibodies, Bispecific | 2 | 2024 | 33 | 0.390 |
Why?
| | src Homology Domains | 1 | 2010 | 34 | 0.370 |
Why?
| | Benzamides | 6 | 2018 | 176 | 0.360 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2020 | 740 | 0.350 |
Why?
| | Imatinib Mesylate | 5 | 2010 | 64 | 0.340 |
Why?
| | Antineoplastic Agents | 4 | 2018 | 1974 | 0.330 |
Why?
| | Transplantation Conditioning | 3 | 2020 | 156 | 0.330 |
Why?
| | Thalidomide | 2 | 2019 | 28 | 0.320 |
Why?
| | Cord Blood Stem Cell Transplantation | 2 | 2020 | 96 | 0.320 |
Why?
| | Oligopeptides | 2 | 2021 | 252 | 0.320 |
Why?
| | Sequence Deletion | 1 | 2008 | 171 | 0.310 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2008 | 407 | 0.300 |
Why?
| | Mutant Proteins | 1 | 2007 | 100 | 0.290 |
Why?
| | Cell Line, Tumor | 5 | 2024 | 2851 | 0.290 |
Why?
| | Humans | 26 | 2024 | 118974 | 0.250 |
Why?
| | Waldenstrom Macroglobulinemia | 1 | 2024 | 11 | 0.240 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2019 | 667 | 0.240 |
Why?
| | Bone Marrow | 3 | 2020 | 255 | 0.230 |
Why?
| | Lymphoma, B-Cell | 1 | 2024 | 85 | 0.220 |
Why?
| | Lymphoma | 1 | 2024 | 180 | 0.220 |
Why?
| | Cell Proliferation | 5 | 2020 | 2275 | 0.220 |
Why?
| | Animals | 9 | 2020 | 33381 | 0.200 |
Why?
| | Biomarkers, Tumor | 1 | 2007 | 1059 | 0.190 |
Why?
| | Graft vs Host Disease | 2 | 2020 | 216 | 0.190 |
Why?
| | Interferon Regulatory Factors | 1 | 2020 | 31 | 0.190 |
Why?
| | Mice | 6 | 2020 | 15520 | 0.190 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2020 | 56 | 0.190 |
Why?
| | Proteasome Inhibitors | 1 | 2020 | 44 | 0.190 |
Why?
| | Primary Cell Culture | 1 | 2020 | 155 | 0.180 |
Why?
| | Heterografts | 1 | 2020 | 130 | 0.180 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2020 | 189 | 0.180 |
Why?
| | Drug Synergism | 1 | 2020 | 339 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2020 | 115 | 0.180 |
Why?
| | Aged | 9 | 2020 | 19657 | 0.180 |
Why?
| | Transplantation, Homologous | 1 | 2021 | 415 | 0.180 |
Why?
| | Endoribonucleases | 1 | 2019 | 64 | 0.170 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 874 | 0.170 |
Why?
| | Thiotepa | 1 | 2018 | 19 | 0.160 |
Why?
| | Clinical Trials as Topic | 2 | 2017 | 969 | 0.160 |
Why?
| | Neuroendocrine Tumors | 1 | 2018 | 83 | 0.150 |
Why?
| | Prostate | 1 | 2018 | 158 | 0.150 |
Why?
| | Melphalan | 1 | 2017 | 30 | 0.150 |
Why?
| | Antigens, Neoplasm | 1 | 2018 | 228 | 0.150 |
Why?
| | Treatment Outcome | 3 | 2021 | 9342 | 0.150 |
Why?
| | Flow Cytometry | 1 | 2020 | 1085 | 0.150 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2017 | 180 | 0.140 |
Why?
| | Male | 11 | 2021 | 57801 | 0.140 |
Why?
| | Middle Aged | 8 | 2020 | 27617 | 0.140 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2016 | 74 | 0.140 |
Why?
| | Wnt Signaling Pathway | 1 | 2018 | 150 | 0.140 |
Why?
| | Salvage Therapy | 1 | 2017 | 130 | 0.140 |
Why?
| | Gene Dosage | 1 | 2016 | 136 | 0.140 |
Why?
| | Protein Structure, Tertiary | 3 | 2007 | 823 | 0.140 |
Why?
| | Immunologic Factors | 1 | 2018 | 225 | 0.130 |
Why?
| | Adult | 8 | 2020 | 31512 | 0.130 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 356 | 0.120 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1166 | 0.120 |
Why?
| | Aged, 80 and over | 4 | 2019 | 6561 | 0.110 |
Why?
| | Signal Transduction | 3 | 2020 | 4709 | 0.110 |
Why?
| | Female | 10 | 2020 | 61565 | 0.110 |
Why?
| | Adenocarcinoma | 1 | 2018 | 812 | 0.100 |
Why?
| | Recurrence | 3 | 2019 | 975 | 0.100 |
Why?
| | Prostatic Neoplasms | 1 | 2018 | 940 | 0.100 |
Why?
| | Immunoblotting | 2 | 2008 | 307 | 0.090 |
Why?
| | Retrospective Studies | 2 | 2023 | 12978 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2008 | 4596 | 0.080 |
Why?
| | Protein Kinases | 1 | 2010 | 310 | 0.080 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2008 | 33 | 0.080 |
Why?
| | Philadelphia Chromosome | 1 | 2007 | 15 | 0.080 |
Why?
| | Tyrosine | 1 | 2008 | 233 | 0.070 |
Why?
| | Cell Line | 2 | 2010 | 2707 | 0.070 |
Why?
| | Janus Kinase 2 | 1 | 2006 | 32 | 0.070 |
Why?
| | RNA, Neoplasm | 1 | 2007 | 77 | 0.070 |
Why?
| | Myeloproliferative Disorders | 1 | 2006 | 26 | 0.070 |
Why?
| | Codon | 1 | 2007 | 89 | 0.070 |
Why?
| | DNA, Neoplasm | 1 | 2007 | 154 | 0.070 |
Why?
| | Remission Induction | 1 | 2007 | 247 | 0.070 |
Why?
| | Treatment Refusal | 1 | 2007 | 86 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-abl | 1 | 2005 | 7 | 0.070 |
Why?
| | DNA Mutational Analysis | 1 | 2007 | 381 | 0.070 |
Why?
| | Bone Marrow Transplantation | 1 | 2006 | 244 | 0.070 |
Why?
| | Models, Molecular | 1 | 2010 | 1435 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2007 | 490 | 0.060 |
Why?
| | src-Family Kinases | 1 | 2005 | 90 | 0.060 |
Why?
| | Protein Conformation | 1 | 2008 | 848 | 0.060 |
Why?
| | Mutation, Missense | 1 | 2006 | 300 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 982 | 0.060 |
Why?
| | Survival Analysis | 2 | 2018 | 1267 | 0.060 |
Why?
| | Phosphorylation | 1 | 2008 | 1633 | 0.060 |
Why?
| | Medical Oncology | 1 | 2023 | 229 | 0.050 |
Why?
| | Cells, Cultured | 1 | 2008 | 4077 | 0.050 |
Why?
| | Cohort Studies | 1 | 2010 | 5116 | 0.050 |
Why?
| | Young Adult | 2 | 2018 | 10793 | 0.050 |
Why?
| | X-Box Binding Protein 1 | 1 | 2019 | 8 | 0.040 |
Why?
| | Bortezomib | 1 | 2019 | 42 | 0.040 |
Why?
| | Unfolded Protein Response | 1 | 2019 | 46 | 0.040 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2019 | 34 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2007 | 2657 | 0.040 |
Why?
| | Androstenes | 1 | 2018 | 11 | 0.040 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2019 | 97 | 0.040 |
Why?
| | Therapeutics | 1 | 2018 | 12 | 0.040 |
Why?
| | Macaca fascicularis | 1 | 2018 | 53 | 0.040 |
Why?
| | Antibody Affinity | 1 | 2018 | 55 | 0.040 |
Why?
| | Phenylthiohydantoin | 1 | 2018 | 40 | 0.040 |
Why?
| | Myeloablative Agonists | 1 | 2018 | 22 | 0.040 |
Why?
| | Vidarabine | 1 | 2018 | 27 | 0.040 |
Why?
| | Fetal Blood | 1 | 2020 | 272 | 0.040 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-6 | 1 | 2018 | 7 | 0.040 |
Why?
| | Myocarditis | 1 | 2019 | 95 | 0.040 |
Why?
| | Whole-Body Irradiation | 1 | 2018 | 72 | 0.040 |
Why?
| | Nitriles | 1 | 2018 | 155 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 736 | 0.040 |
Why?
| | Wnt Proteins | 1 | 2018 | 140 | 0.040 |
Why?
| | Maximum Tolerated Dose | 1 | 2017 | 185 | 0.040 |
Why?
| | Administration, Oral | 1 | 2019 | 756 | 0.040 |
Why?
| | Transplantation, Autologous | 1 | 2017 | 191 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 842 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1125 | 0.030 |
Why?
| | beta Catenin | 1 | 2018 | 219 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2018 | 653 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2018 | 454 | 0.030 |
Why?
| | Biopsy | 1 | 2019 | 1079 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1720 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1691 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1167 | 0.030 |
Why?
| | Hematopoietic Stem Cells | 2 | 2006 | 359 | 0.030 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2018 | 532 | 0.030 |
Why?
| | Disease Progression | 1 | 2019 | 2490 | 0.030 |
Why?
| | Prognosis | 1 | 2019 | 3443 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 3588 | 0.020 |
Why?
| | Hematopoiesis, Extramedullary | 1 | 2006 | 5 | 0.020 |
Why?
| | Polycythemia Vera | 1 | 2006 | 13 | 0.020 |
Why?
| | Polycythemia | 1 | 2006 | 26 | 0.020 |
Why?
| | Receptors, Erythropoietin | 1 | 2006 | 25 | 0.020 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2006 | 70 | 0.020 |
Why?
| | Clone Cells | 1 | 2006 | 248 | 0.020 |
Why?
| | Erythropoietin | 1 | 2006 | 82 | 0.020 |
Why?
| | Phosphotyrosine | 1 | 2005 | 37 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2005 | 81 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2006 | 273 | 0.020 |
Why?
| | Dasatinib | 1 | 2005 | 46 | 0.020 |
Why?
| | Time Factors | 2 | 2006 | 6412 | 0.020 |
Why?
| | Thiazoles | 1 | 2005 | 121 | 0.020 |
Why?
| | Spleen | 1 | 2006 | 510 | 0.020 |
Why?
| | Point Mutation | 1 | 2005 | 228 | 0.020 |
Why?
| | Transfection | 1 | 2006 | 888 | 0.020 |
Why?
| | Genetic Vectors | 1 | 2005 | 302 | 0.020 |
Why?
| | Fibrosis | 1 | 2006 | 483 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2006 | 1206 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 2005 | 439 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2006 | 1171 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 1945 | 0.010 |
Why?
| | Stem Cells | 1 | 2005 | 559 | 0.010 |
Why?
|
|
Sherbenou's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|